abagovomab (ACA 125)
/ Menarini
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 14, 2019
Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis.
(PubMed, Cancer Manag Res)
- "However, anti-CA-125 monoclonal antibodies (abagovomab and oregovomab) showed no significant survival benefit. Our study showed a survival advantage conferred by pazopanib and bevacizumab as maintenance therapy in newly diagnosed epithelial ovarian cancer. Further clinical trials are essential to both determine the effect of bevacizumab in the maintenance stage and identify the specific subgroup(s) that benefit."
Journal • Retrospective data
1 to 1
Of
1
Go to page
1